GleamWall
中文EN

PMHS Polomar Health Services, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1265521 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11,701.9%
TTM net income YoY-303.9%
TTM EPS YoY-300.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin49.1%
Operating margin-221.0%
Net margin-224.6%
FCF margin—
EBITDA margin-14.8%

Returns

ROE-469.6%
ROA-193.3%
ROIC (approx.)-392.6%
Asset turnover0.86x

Leverage & solvency

Liabilities / assets325.5%
Debt / equity—
Current ratio0.24x
Interest coverage-61.19x

Cash quality & payout

Operating cash flow / net income-0.04x
Accruals ratio-200.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$648,231$58,824
Cost of revenue$188,132$27,921
Gross profit$460,099$30,903
SG&A expense$10.94M$1.28M
Operating income-$10.55M-$1.30M
Interest expense$150,841$41,837
Net income-$10.70M-$1.34M
EBITDA-$776,936-$1.04M
EPS (basic)-0.39-0.05
EPS (diluted)-0.39-0.05
Weighted avg. shares (diluted)27.76M27.66M
Balance sheet
Cash & equivalents$132,150$6,191
Inventory$93,636$68,777
Current assets$322,727$76,813
PP&E, net$43,452$81,405
Total assets$390,043$9.95M
Current liabilities$1.61M$1.34M
Total liabilities$1.61M$1.35M
Shareholders' equity-$1.97M$8.60M
Shares outstanding28.02M27.66M
Cash flow statement
Operating cash flow-$395,995-$1.02M
Capital expenditure—$90,893
Free cash flow—-$1.11M
Investing cash flow—-$90,893
Financing cash flow$521,954$1.11M
Depreciation & amortization$9.77M$263,280
Stock-based compensation$129,645—

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.